Celyad Oncology SA (EBR:CYAD)
Belgium
· Delayed Price · Currency is EUR 0.311
-0.007 (-2.20%)
Apr 29, 2026, 9:16 AM CET
Celyad Oncology Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 0.02 | 0.19 | 0.1 | - | - | Upgrade
|
| Revenue Growth (YoY) | -88.71% | 82.35% | - | - | - | Upgrade
|
| Cost of Revenue | 0.01 | 0.01 | 0.07 | - | - | Upgrade
|
| Gross Profit | 0.01 | 0.17 | 0.03 | - | - | Upgrade
|
| Selling, General & Admin | 3.78 | 3.2 | 6.25 | 10.56 | 10 | Upgrade
|
| Research & Development | 3.42 | 3.24 | 4.38 | 18.91 | 20.69 | Upgrade
|
| Other Operating Expenses | -5.66 | -0.39 | -1.05 | -4.03 | -3.44 | Upgrade
|
| Operating Expenses | 1.54 | 6.04 | 9.58 | 25.45 | 27.24 | Upgrade
|
| Operating Income | -1.53 | -5.87 | -9.54 | -25.45 | -27.24 | Upgrade
|
| Interest Expense | -0.06 | -0.1 | -0.08 | -0.2 | -0.26 | Upgrade
|
| Interest & Investment Income | 0.01 | 0.15 | 0.03 | 0.01 | 0.03 | Upgrade
|
| Currency Exchange Gain (Loss) | - | -0.02 | - | 0.17 | 0.01 | Upgrade
|
| Other Non Operating Income (Expenses) | 0 | -0 | - | -0 | 0.11 | Upgrade
|
| EBT Excluding Unusual Items | -1.58 | -5.84 | -9.6 | -25.46 | -27.35 | Upgrade
|
| Impairment of Goodwill | - | - | - | -0.64 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 2.31 | 0.01 | 1.09 | 5 | -0 | Upgrade
|
| Asset Writedown | - | - | - | -34.44 | - | Upgrade
|
| Other Unusual Items | 0.1 | - | - | 14.68 | 0.85 | Upgrade
|
| Pretax Income | 0.83 | -5.82 | -8.51 | -40.87 | -26.5 | Upgrade
|
| Income Tax Expense | - | - | -0.06 | 0.07 | 0.01 | Upgrade
|
| Net Income | 0.83 | -5.82 | -8.45 | -40.94 | -26.51 | Upgrade
|
| Net Income to Common | 0.83 | -5.82 | -8.45 | -40.94 | -26.51 | Upgrade
|
| Shares Outstanding (Basic) | 43 | 41 | 26 | 23 | 16 | Upgrade
|
| Shares Outstanding (Diluted) | 46 | 41 | 26 | 23 | 16 | Upgrade
|
| Shares Change (YoY) | 11.68% | 61.06% | 13.84% | 44.80% | 11.92% | Upgrade
|
| EPS (Basic) | 0.02 | -0.14 | -0.33 | -1.81 | -1.70 | Upgrade
|
| EPS (Diluted) | 0.02 | -0.14 | -0.33 | -1.81 | -1.70 | Upgrade
|
| Free Cash Flow | -6.9 | -5.68 | -16.1 | -28.13 | -26.97 | Upgrade
|
| Free Cash Flow Per Share | -0.15 | -0.14 | -0.63 | -1.25 | -1.73 | Upgrade
|
| Gross Margin | 61.91% | 93.55% | 32.35% | - | - | Upgrade
|
| Operating Margin | -7261.90% | -3155.38% | -9356.86% | - | - | Upgrade
|
| Profit Margin | 3952.38% | -3131.18% | -8282.35% | - | - | Upgrade
|
| Free Cash Flow Margin | -32857.14% | -3053.76% | -15785.29% | - | - | Upgrade
|
| EBITDA | -1.52 | -5.69 | -9.04 | -24.74 | -26.68 | Upgrade
|
| D&A For EBITDA | 0.01 | 0.18 | 0.51 | 0.71 | 0.56 | Upgrade
|
| EBIT | -1.53 | -5.87 | -9.54 | -25.45 | -27.24 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.